PicoCELA Inc. (NASDAQ:PCLA) Short Interest Down 19.2% in February

PicoCELA Inc. (NASDAQ:PCLA) saw a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 10,866 shares, a decline of 19.2% from the February 12th total of 13,443 shares. Based on an average daily volume of 6,078 shares, the short-interest ratio is currently 1.8 days. Approximately 27.2% of the shares of the company are sold short. Approximately 27.2% of the shares of the company are sold short. Based on an average daily volume of 6,078 shares, the short-interest ratio is currently 1.8 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

PicoCELA Stock Performance

Shares of NASDAQ PCLA traded up $0.08 during trading on Monday, hitting $2.33. 15,693 shares of the company were exchanged, compared to its average volume of 50,844. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.13 and a quick ratio of 1.57. PicoCELA has a 1 year low of $2.17 and a 1 year high of $112.20. The firm’s fifty day moving average price is $5.36 and its 200 day moving average price is $9.14.

Institutional Trading of PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. Jane Street Group LLC bought a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned 18.92% of PicoCELA at the end of the most recent quarter.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.